Table 1.
Patient characteristics. Patients could be included more than once and an inclusion is referred to as “on‐protocol episode”. A variable number of observation days per inclusion are incorporated. The cardiovascular risk profile is defined as one or more of the following comorbidities: hypertension, diabetes mellitus, TIA/CVA, peripheral artery disease, ischemic congestive heart failure, or myocardial infarction.
| n = 116 on‐protocol episodes | |
|---|---|
| Age [years; mean (±SD)] | 54 (±12) |
| Gender (male/female; n/n) | 75/41 |
| Diagnosis n (%) | |
| MDS/AML (myelodysplastic syndrome/acute myeloid leukemia) | 43 (37%) |
| MM (multiple myeloma) | 33 (28%) |
| NHL (non hodgkin lymphoma) | 27 (23%) |
| ALL (acute lymphoblastic leukemia) | 6 (6%) |
| Other (Hodgkin’s lymphoma, mantle cell lymphoma, chronic leukaemia) | 7 (6%) |
| Treatment n (%) | |
| Autologous transplantation | 66 (57%) |
| Remission induction chemotherapy | 32 (28%) |
| Consolidation chemotherapy | 12 (10%) |
| Allogeneic transplantation | 6 (5%) |
| Randomization arm in PREPAReS trial n (%) | |
| Control (plasma stored platelet concentrates) | 57 (49%) |
| Intervention (pathogen‐reduced platelet concentrates) | 59 (51%) |
| Number of observation days per on‐protocol episode median (IQR) with | |
| Daily bleeding assessment | 16 (12–20) |
| Measurement morning platelet count | 13 (10–17) |
| Measurement urine albumin/creatinine ratio | 4 (2–5) |
| Measurement of serum C‐reactive protein | 3 (2–5) |
| Cardiovascular risk profile present* n (%) | 30 (28·6%) |
| Fever present n (%) of days | 336 (29·5%) |
ALL, acute lymphoblastic leukemia; IQR, interquartile range; MDS/AML, myelodysplastic syndrome/acute myeloid leukemia; MM, multiple myeloma; NHL, non hodgkin lymphoma.
*
Measurement available for 105/116 on‐protocol episodes.